Our Progress
We strive to move scientific discoveries rapidly from the lab to the clinic to make a difference to patients’ lives as fast as possible. Find out more about our pipeline here.
Factor B
STL303
STL303 is an oral once daily small molecule that is a potent, highly selective inhibitor of complement factor B.
Geographic atrophy
Age related macular degeneration (AMD) is classified into early, intermediate, and late-stage disease. Late-stage AMD includes two subtypes: Geographic atrophy (GA) and choroidal neovascularisation (CNV).
GA results in loss of retinal cells, leading to a blurred area or blind spot. Studies link genetics, inflammation and complement activation to AMD.
STL303 halts inflammation by inhibiting complement factor B, with the aim to preserve retinal cells and ultimately vision.
IgA Nephropathy
IgA nephropathy (IgAN), is an autoimmune condition resulting in glomerulonephritis and renal failure.
B cells produce abnormally glycosylated IgA1 (Gd-IgA1). The immune system recognises Gd-IgA1s as abnormal and produces autoantibodies against these, triggering the formation of immune complexes that deposit in kidney causing inflammation, complement activation and damage to the kidney.
Our small molecule, STL303, inhibits factor B, a key regulator in IgAN, thereby aiming to inhibit immune complex mediated damage and preserve kidney function.
Target X
Target Y
Find Out More
Discover more with the latest updates and news on our company and programs.